Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
18 Cards in this Set
- Front
- Back
oral contraceptive use influence on ovarian cancer
|
OCP use decreases risk of ovarian cancer
|
|
biggest factor in decreasing risk of ovarian cancer
|
decreased number of ovulatory cycles (OC's, mult pregnancies, tubal ligation, etc)
|
|
BRCA-1 and BRCA-2 mutation influence on ovarian ca
|
survival better in pts w/ BRCA-1 or -2 mutations than sporadic cancer
|
|
ovarian screening
|
no effective screening test
|
|
recommendation for women at low/standard risk ovarian
|
annual physical and pelvic exam
|
|
recommendation for women at high risk ovarian
|
pelvic exam, transvaginal ultrasound and CA-125 every 6-12 months starting at age 25-35
|
|
normal range for CA-125
|
0-35 U/mL
|
|
treatment: early stage ovarian w/ favorable features
|
surgery
|
|
treatment: early stage ovarian w/ unfavorable features
|
surgery followed by
paclitaxel + carbo q3w x 6 cyc |
|
treatment: ovarian stage II- 2 alternatives
|
1) IP+IV chemo
2) docetaxel + carbo q3w x 6 |
|
treatment: ovarian stage III & IV
|
surgery + chemo of taxane & platinum x 6 cycles. IP chemo is preferred route for select pts
|
|
carbo vs cisplatin in ovarian
|
carbo preferred due to less toxicity and equal efficacy
|
|
cisplatin + paclitaxel q3w same day recommendation in ovarian
|
not recommended for routine use due to increased neurotoxicity
|
|
docetaxel vs paclitaxel in ovarian
|
docetaxel is less neurotoxic and equally effective
|
|
treatment options for recurrent ovarian cancer
|
1) paclitaxel + carbo
2) gemcitabine + carbo 3) carbo single agent 4) paclitaxel single agent |
|
salvage agents for ovarian cancer
|
Doxil, topotecan, vinorelbine
|
|
CA-125 laboratory variation
|
significant, should draw at same lab for consistency
|
|
Ovarian cancer symptoms: (4)
|
bloating, pelvic/abdominal pain, difficulty eating or feeling full, urinary symptoms
|